tetano
Editor, Senior Moderator
J Med Virol
. 2021 Oct 14.
doi: 10.1002/jmv.27394. Online ahead of print.
Postvaccination SARS-CoV-2 Alpha (B.1.1.7) Lineage Infection among Healthcare Workers on the Background of IgG Antibodies
Ivailo Alexiev[SUP] 1 [/SUP], Ivan Ivanov[SUP] 1 [/SUP], Ivva Philipova[SUP] 1 [/SUP], Nelly Korsun[SUP] 1 [/SUP], Ivan Stoykov[SUP] 1 [/SUP], Reneta Dimitrova[SUP] 1 [/SUP], Lubomira Grigorova[SUP] 1 [/SUP], Anna Gancheva[SUP] 1 [/SUP], Ivelina Trifonova[SUP] 1 [/SUP], Veselin Dobrinov[SUP] 1 [/SUP], Iliana Grigorova[SUP] 1 [/SUP], Alexey Savov[SUP] 2 [/SUP], Boryana Asenova[SUP] 3 [/SUP], Massimo Ciccozzi[SUP] 4 [/SUP], Todor Kantardjiev[SUP] 1 [/SUP]
Affiliations
Abstract
Like most vaccines, the effectiveness of COVID-19 vaccines developed so far is not 100% and a small percentage of fully vaccinated individuals still develop symptomatic or asymptomatic SARS-CoV-2 infections. [SUP]1[/SUP] In addition, the emerging of novel mutations is likely to help the virus evade vaccines especially in regions with low vaccination coverage. [SUP]2[/SUP] This article is protected by copyright. All rights reserved.
Keywords: Pandemics < Epidemiology; SARS coronavirus < Virus classification; Vaccines/Vaccine strains < Disease control.
. 2021 Oct 14.
doi: 10.1002/jmv.27394. Online ahead of print.
Postvaccination SARS-CoV-2 Alpha (B.1.1.7) Lineage Infection among Healthcare Workers on the Background of IgG Antibodies
Ivailo Alexiev[SUP] 1 [/SUP], Ivan Ivanov[SUP] 1 [/SUP], Ivva Philipova[SUP] 1 [/SUP], Nelly Korsun[SUP] 1 [/SUP], Ivan Stoykov[SUP] 1 [/SUP], Reneta Dimitrova[SUP] 1 [/SUP], Lubomira Grigorova[SUP] 1 [/SUP], Anna Gancheva[SUP] 1 [/SUP], Ivelina Trifonova[SUP] 1 [/SUP], Veselin Dobrinov[SUP] 1 [/SUP], Iliana Grigorova[SUP] 1 [/SUP], Alexey Savov[SUP] 2 [/SUP], Boryana Asenova[SUP] 3 [/SUP], Massimo Ciccozzi[SUP] 4 [/SUP], Todor Kantardjiev[SUP] 1 [/SUP]
Affiliations
- PMID: 34647629
- DOI: 10.1002/jmv.27394
Abstract
Like most vaccines, the effectiveness of COVID-19 vaccines developed so far is not 100% and a small percentage of fully vaccinated individuals still develop symptomatic or asymptomatic SARS-CoV-2 infections. [SUP]1[/SUP] In addition, the emerging of novel mutations is likely to help the virus evade vaccines especially in regions with low vaccination coverage. [SUP]2[/SUP] This article is protected by copyright. All rights reserved.
Keywords: Pandemics < Epidemiology; SARS coronavirus < Virus classification; Vaccines/Vaccine strains < Disease control.